In the last three months, 12 analysts have published ratings on Merit Medical Systems (NASDAQ:MMSI), offering a diverse range of perspectives from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 5 | 7 | 0 | 0 | 0 |
| Last 30D | 0 | 1 | 0 | 0 | 0 |
| 1M Ago | 2 | 2 | 0 | 0 | 0 |
| 2M Ago | 2 | 2 | 0 | 0 | 0 |
| 3M Ago | 1 | 2 | 0 | 0 | 0 |
Analysts have recently evaluated Merit Medical Systems and provided 12-month price targets. The average target is $117.08, accompanied by a high estimate of $128.00 and a low estimate of $109.00. This current average reflects an increase of 1.17% from the previous average price target of $115.73.
Analyzing Analyst Ratings: A Detailed Breakdown
A comprehensive examination of how financial experts perceive Merit Medical Systems is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Robbie Marcus | JP Morgan | Announces | Overweight | $120.00 | - |
| Michael Petusky | Barrington Research | Lowers | Outperform | $111.00 | $115.00 |
| Jon Young | Canaccord Genuity | Lowers | Buy | $127.00 | $128.00 |
| Larry Biegelsen | Wells Fargo | Lowers | Overweight | $117.00 | $120.00 |
| Mike Matson | Needham | Lowers | Buy | $116.00 | $122.00 |
| Jason Bednar | Piper Sandler | Raises | Overweight | $116.00 | $114.00 |
| Michael Petusky | Barrington Research | Raises | Outperform | $115.00 | $114.00 |
| Jon Young | Canaccord Genuity | Raises | Buy | $128.00 | $127.00 |
| Mike Matson | Needham | Raises | Buy | $122.00 | $109.00 |
| Jason Bednar | Piper Sandler | Raises | Overweight | $114.00 | $110.00 |
| Mike Matson | Needham | Maintains | Buy | $109.00 | $109.00 |
| Jayson Bedford | Raymond James | Raises | Outperform | $110.00 | $105.00 |
Key Insights:
- Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Merit Medical Systems. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Merit Medical Systems compared to the broader market.
- Price Targets: Delving into movements, analysts provide estimates for the future value of Merit Medical Systems's stock. This analysis reveals shifts in analysts' expectations over time.
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Merit Medical Systems's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
Stay up to date on Merit Medical Systems analyst ratings.
Delving into Merit Medical Systems's Background
Merit Medical Systems Inc is a medical equipment company that develops and manufactures products for interventional cardiology, radiology, and endoscopy procedures. The firm reports two segments which are Cardiovascular and Endoscopy. The majority of the revenue is earned from the Cardiovascular segment which consists of cardiology and radiology medical device products that assist in diagnosing and treating coronary artery disease, peripheral vascular disease, and other non-vascular diseases and includes embolotherapeutic, cardiac rhythm management, electrophysiology, critical care, and interventional oncology and spine devices.
Financial Milestones: Merit Medical Systems's Journey
Market Capitalization Analysis: With an elevated market capitalization, the company stands out above industry averages, showcasing substantial size and market acknowledgment.
Revenue Growth: Over the 3 months period, Merit Medical Systems showcased positive performance, achieving a revenue growth rate of 9.44% as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 7.87%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Merit Medical Systems's ROE excels beyond industry benchmarks, reaching 2.07%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 1.17%, the company showcases effective utilization of assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.58.
The Significance of Analyst Ratings Explained
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. Click here to stay ahead of the market.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
